Trump discussed Iran’s Hormuz Strait proposal with top aides, White House says
The Trump administration has repeatedly insisted that the central goal of the conflict is keeping Iran from ever obtaining a nuclear weapon.
Former Google DeepMind researcher’s AI startup raises record $1.1 billion seed funding to pursue superintelligence
Ineffable Intelligence has emerged from stealth with a $5.1 billion valuation.
Prediction markets prepare to invade one of crypto’s biggest and riskiest trades
There’s a land grab underway in the U.S. for perpetual futures, one of the biggest and riskiest parts of crypto — and prediction markets want a piece of it.
OpenAI shakes up partnership with Microsoft, capping revenue share payments
Things have changed since Microsoft and OpenAI announced a broad agreement following OpenAI’s restructuring in October.
The energy crisis will boost nuclear power, the IEA told CNBC. Here’s how investors can benefit
The nuclear power theme can be accessed in several ways: mining and refining stocks, as well as through the spot uranium price via ETFs and holding companies.
Oil giant Shell to buy Canada’s ARC Resources for $16.4 billion in push to boost output
The transaction will add roughly 370,000 barrels of oil equivalent per day to Shell’s portfolio and is designed to boost the firm’s long-term production.
Qualcomm up 7% on report it’s partnering with OpenAI on smartphone AI chip
Qualcomm will be working alongside MediaTek to develop a smartphone chip for OpenAI, with manufacturer Luxshare co-designing the device, an analyst said.
China’s tech play, U.S. high yield & own equities — 3 investment strategies from the studio
Here are three investment strategies we heard out of CNBC’s London and Singapore studios on Monday to help navigate the noise.
United Airlines CEO confirms he approached American Airlines about merger
United CEO Scott Kirby said American rejected the idea, “and without a willing partner, something this big simply can’t get done.”
Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial
Intellia Therapeutics said its Crispr-based treatment for hereditary angioedema met its goals in a Phase 3 trial, marking a milestone for gene editing.
